November: HCV/HBV Newsletter At HCV Advocate

Sunday, October 31, 2010

November: HCV/HBV Newsletter At HCV Advocate

November 2010 HCV Advocate
Download printable version
--------
In This Issue:
Two Important Discoveries

Alan Franciscus, Editor-in-Chief

Disability & Benefits: It’s Open Enrollment Time Again

Jacques Chambers, CLU

HealthWise: Living Donation Liver Transplantation

Lucinda Porter, RN

HCV Snapshots

AASLD 2010 HCV Coverage

Click Here

New: Viral Hepatitis and Liver Stages

Click Here

Lucinda Porter, RNAlan Franciscus, Editor-in-ChiefHCV Advocate Eblast

Stay informed on the latest news ..click here to register for email alerts

HCVAdvocate

———————————————

Join us on Facebook

Hcvadvocate Hcsp

.
HBV Journal Review
HBV Journal ReviewNovember 1, 2010,

Special "Occult HBV"

Issue:Click Here

Vol 7, no 11 by Christine M. Kukka

AASLD 2010 HBV Coverage

Click Here

Action Alert Oct 2010

Hepatitis & Liver CancerAction Alert

Click Here

HBVAdvocate

No comments:

Post a Comment

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.

HCV New Drugs

Risk Of Developing Liver Cancer After HCV Treatment

Sunday, October 31, 2010